Floyd & Delores Jones Cancer Institute

Virginia Mason First in Pacific Northwest to Offer Neuroendocrine Tumor Treatment

The epitome of frustration is when you are experiencing symptoms that have taken control of your life and medical professionals can’t find a way to alleviate them. For more than five years, that was Gig Harbor resident Ellen Dunn’s life.

She suffered with ongoing cramping, diarrhea and dry flushing of her skin. She was first diagnosed with Irritable Bowel Syndrome, but that was incorrect. “No matter what was prescribed, my symptoms just kept getting worse. It was ruining my life,” Ellen remembers. “I told my internist it’s got to be something else. She recommended I take a blood test for carcinoid syndrome, and that’s what it was.”

Finally, Ellen had an answer. Malignant carcinoid tumors tend to grow slowly. But when they increase in size, they cause pain and can produce hormones that cause diarrhea, flushing and disrupt the body’s endocrine system. Standard chemotherapy and radiation aren’t effective on these types of tumors.


Ellen Dunn is one of two Virginia Mason patients in the Pacific Northwest to benefit from a therapy targeting neuroendocrine or carcinoid tumors, an uncommon cancer that affects the intestines, pancreas, lungs and other parts of the body.

Fortunately for Ellen, she learned she had carcinoid tumors at the same time a treatment to control the growth of neuroendocrine or carcinoid tumors (NET) was going through a clinical trial, led by Hagen Kennecke, MD, oncologist and medical director of the Floyd & Delores Jones Cancer Institute at Virginia Mason. Along with another Virginia Mason patient, Ellen was selected to be one of the first two patients in the Pacific Northwest to receive this treatment.

Called peptide receptor radionuclide therapy (PRRT), the treatment involves an injection of a small protein peptide into the patient’s bloodstream. The peptide finds the cancer tumors and binds to them, while also protecting the surrounding tissues. PRRT has been shown to significantly stop the growth of tumors for on average two and a half years. It is also beneficial to patients with advanced neuroendocrine tumors who are not candidates for surgery and whose symptoms are not responding to other medical treatment.

In December, Dr. Kennecke and radiologist Marie Lee, MD, administered Ellen’s first treatment. She receives PRRT treatments every two months in an outpatient setting. The treatment takes only a few hours and has minimal side effects. Ellen had her third PRRT treatment in April.

“I’m so thankful that I was accepted into the program,” Ellen says. “I feel very fortunate.”

“Until now, there has been no effective therapy to shrink small bowel and lung neuroendocrine tumors when surgery is not an option,” says Dr. Kennecke. “While this procedure does not cure cancer, it significantly extends the lives of those living with the disease and improves their quality of life. We are proud to be on the forefront of this promising, highly targeted therapy, which can be used for the treatment of other cancers in the future.”

More than 3,000 patients with advanced carcinoid tumors live in Washington state. This new treatment helps the majority of these cancer patients and controls the tumors for three years on average. The treatment may be repeated as needed.

“I’m so thankful that I was accepted into the program,” Ellen says. “I feel very fortunate.”

In early April 2018, Virginia Mason became the first medical center in the Pacific Northwest to administer PRRT as part of routine care, offering a viable new treatment to many patients. In the near future, Virginia Mason will be offering clinical trials of a very similar therapy to treat patients with prostate cancer.